May 7, 2025 /PRNewswire/ -- Mana.bio, a biotechnology company leveraging artificial intelligence (AI) and nanotechnology for targeted RNA delivery ... AI / ML to design LNP for delivering nucleic ...

The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as a genetic instruction book, telling cells to produce therapeutic or ...

Research teams across Canada are now building on homegrown innovation to expand the potential of RNA vaccines beyond ...

CPD-accredited course delivered in an engaging way by our incredible RNA and LNP experts with videos and animation. There's also the opportunity to ask any burning questions in a dedicated Q&A session ...

unmodified RNA or impurities can overstimulate the innate immune system, causing inflammation or adverse reactions. Although techniques like chemical modification and LNP encapsulation help reduce ...

LNPs can carry gene editing machinery like Cas9 mRNA or guide RNA into cells. This opens the ability for LNPs to be used as a delivery system for gene therapy. At the moment, there is an LNP-based ...

PNI’s lipid nanoparticles (LNPs) protect the RNA payload and release it into the interior of the target cell through receptor-mediated endocytosis. PNI’s proprietary library of LNP ...

The structure of CL4F 8-6, the branched ionizable lipid that was most effective in increasing storage stability and LNP-RNA delivery (Image: Yusuke Sato).

About Mana.bio Mana.bio is a biotechnology company revolutionizing targeted RNA delivery using artificial intelligence-enabled LNP discovery and optimization. This approach accelerates research ...